Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Beigene Ltd ADR
(NQ:
BGNE
)
156.39
+1.31 (+0.84%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
104,129
Open
157.00
Bid (Size)
151.00 (1)
Ask (Size)
160.00 (8)
Prev. Close
155.08
Today's Range
155.09 - 157.38
52wk Range
132.95 - 272.49
Shares Outstanding
1,211,067,023
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
4 Analysts Assess BeiGene: What You Need To Know
March 27, 2024
Via
Benzinga
Week In Review: Three Multinationals Plan Investments In Southeast Asia Facilities
March 23, 2024
Shanghai WuXi Biologics has broken ground on a $1.4 billion facility in Singapore. Meanwhile, Novo Nordisk announced plans to invest $556 million to expand its Tianjin city production facility.
Via
Talk Markets
Performance
YTD
-11.64%
-11.64%
1 Month
-12.97%
-12.97%
3 Month
-12.86%
-12.86%
6 Month
-15.08%
-15.08%
1 Year
-29.47%
-29.47%
More News
Read More
Lululemon Issues Weak Outlook, Joins Nike And Other Big Stocks Moving Lower In Friday's Pre-Market Session
March 22, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
FDA Approves BeiGene's First Drug Candidate Produced Through Its Immuno-Oncology Program For Esophageal Cancer
March 15, 2024
Via
Benzinga
Exposures
Product Safety
BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy
March 14, 2024
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Ltd. (NASDAQ: BGNE) is a Leading Gainer in 3/13 Morning Trading
March 13, 2024
Via
Investor Brand Network
Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
March 13, 2024
Via
Benzinga
First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation
March 13, 2024
From
BeiGene
Via
Business Wire
Beauty Health Posts Upbeat Sales, Joins SIGA Technologies, MaxCyte And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session
March 13, 2024
Via
Benzinga
FDA Conditionally Approves Expanded Use Of BeiGene's Combination Drug For Certain Type Of Blood Cancer
March 08, 2024
Via
Benzinga
Exposures
Product Safety
BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma
March 07, 2024
From
BeiGene, Ltd.
Via
Business Wire
BeiGene to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024
March 06, 2024
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Announces New Efficacy Analysis Comparing BRUKINSA® vs Acalabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
February 29, 2024
From
BeiGene, Ltd.
Via
Business Wire
BeiGene to Present at Upcoming Investor Conferences
February 28, 2024
From
BeiGene, Ltd.
Via
Business Wire
BeiGene’s Biologics License Application for TEVIMBRA® (tislelizumab) for First-Line Gastric or Gastroesophageal Junction Cancers Accepted by FDA
February 27, 2024
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
February 26, 2024
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Receives Positive CHMP Opinion for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
February 26, 2024
From
BeiGene, Ltd.
Via
Business Wire
Hang Seng Index Set For Global Expansion With Prada, XPeng, And BeiGene On The Horizon
February 16, 2024
Via
Benzinga
Get Rich Quick With These 3 Biotech Stocks to Buy Now
February 13, 2024
Via
InvestorPlace
3 Strong Buy Biotech Stocks to Add to Your February Must-Watch List
February 06, 2024
Via
InvestorPlace
JP Morgan's Bullish View On This Chinese Biotech, Says Pullback Creates Entry Point
February 06, 2024
Via
Benzinga
BeiGene Welcomes Experienced Life Sciences Executive Olivier Brandicourt to Board of Directors
January 23, 2024
From
BeiGene, Ltd.
Via
Business Wire
5 Biotech Stocks That Could Be Big Winners in 2024 and Beyond
January 15, 2024
Via
The Motley Fool
As China's Population Declines In 2023, Will Aging Demographics Boost Healthcare Stocks?
January 10, 2024
Via
Benzinga
3 Top Biotech Stocks Worth Adding To Your Portfolio In 2024
January 07, 2024
Via
Talk Markets
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.